![]() | A major contributor to this article appears to have a close connection with its subject.(August 2025) |
![]() | |
Formerly | Tempus Labs |
---|---|
Company type | Public |
Nasdaq: TEM | |
Industry | Health technology |
Founded | 2015 |
Founder | Eric Lefkofsky |
Headquarters | Chicago, Illinois, US |
Key people | Eric Lefkofsky (CEO) |
Number of employees | 2,300 (2024) |
Website | tempus.com |
Tempus AI, Inc. (formerly Tempus Labs [1] ) is an American health technology company [2] founded in 2015 by Eric Lefkofsky in Chicago, Illinois. [3] It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. [4] Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM." [6] [7]
Tempus does genome sequencing and precision medicine, including diagnostics, primarily for cancer patients, as well as for cardiology patients, radiology, and pharmacogenomic testing for patients with depression. [8] It is headquartered in Chicago. [9]
Tempus investors include SoftBank Group, Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, Google LLC, and others. [10]
In June 2024, Tempus and SoftBank formed an AI healthcare joint venture in Japan called SB Tempus with a plan to develop personalized treatment recommendations by analyzing medical data with AI. [11] [12] In November that year, Tempus agreed to acquire California-based genetic testing company Ambry Genetics for $600 million in a cash-and-stock deal. [13]
The company's advisory board includes Jennifer Doudna and Scott Gottlieb. [1] As of 2024, Tempus employs around 2,300 people. [14]